Abatacept: A Review of the Treatment of Polyarticular-Course Juvenile Idiopathic Arthritis

Brunner, Hermine I.; Wong, Robert; Nys, Marleen; Kou, Tzuyung D.; Dominique, Alyssa; Martini, Alberto; Lovell, Daniel J.; Ruperto, Nicolino

doi:10.1007/s40272-020-00422-2

Cited by 15 publications

(10 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…ABA shows a favorable safety profile in both clinical trials, registry data, and real-world evidence, as reviewed by Brunner et al [37 ▪ ]. Clinical trials reported at least one adverse event in 88–100% of patients (173–426/100PY), but SAEs in only 7–20% (4–6/100PY) [37 ▪ ].…”

Section: Costimulatory Inhibitorsmentioning

confidence: 99%

“…Clinical trials reported at least one adverse event in 88–100% of patients (173–426/100PY), but SAEs in only 7–20% (4–6/100PY) [37 ▪ ]. Most common infections included nasopharyngitis, upper respiratory infections, and influenza [37 ▪ ]. Serious infections included appendicitis, limb abscess, impetigo, herpes zoster infection, varicella, and bacterial arthritis [37 ▪ ].…”

Section: Costimulatory Inhibitorsmentioning

confidence: 99%

“…Most common infections included nasopharyngitis, upper respiratory infections, and influenza [37 ▪ ]. Serious infections included appendicitis, limb abscess, impetigo, herpes zoster infection, varicella, and bacterial arthritis [37 ▪ ]. One death and two malignancies in two separate ABA trials were deemed unrelated to treatment.…”

Section: Costimulatory Inhibitorsmentioning

confidence: 99%

“…One death and two malignancies in two separate ABA trials were deemed unrelated to treatment. Real-world safety evidence in 423 pJIA patients with up to 5 years of follow-up revealed five serious infections (≤1/100PY) and 15 autoimmune events (2/100 PY), including new alopecia areata, uveitis, psoriasis, and IBD [37 ▪ ]. One death unrelated to treatment and no malignancies were reported [37 ▪ ].…”

Section: Costimulatory Inhibitorsmentioning

confidence: 99%

“…Real-world safety evidence in 423 pJIA patients with up to 5 years of follow-up revealed five serious infections (≤1/100PY) and 15 autoimmune events (2/100 PY), including new alopecia areata, uveitis, psoriasis, and IBD [37 ▪ ]. One death unrelated to treatment and no malignancies were reported [37 ▪ ]. The BIKER registry reported no serious infections in 105 patients with JIA [11 ▪▪ ].…”

Section: Costimulatory Inhibitorsmentioning

confidence: 99%

See 4 more Smart Citations

Safety updates in novel therapeutics for pediatric rheumatic disease

Randell

Becker

2021

Current Opinion in Rheumatology

View full text Add to dashboard Cite

Purpose of reviewBiologics and novel targeted therapeutics have transformed the management of pediatric rheumatic diseases over the past two decades; however, questions about short-term and long-term safety remain. Safety data gathered from recent clinical trials, long-term extensions of prior trials, registries, and other real-world evidence are summarized here for biologics and novel therapeutics commonly prescribed for pediatric rheumatic diseases. Recent findingsWith nearly 20 years of therapeutic experience, tumor necrosis inhibitors (TNFi) are generally well tolerated, although infections, malignancy, and development of new autoimmunity remain a concern. Risk of infections may be higher in IL-1 and IL-6 inhibitors, and lower in abatacept, compared with TNFi. Safety data for B-cell-targeted therapeutics and janus kinase inhibitors are emerging, but remain limited, especially in children. SummaryBiologic and novel targeted therapeutics offer a promising future for children with pediatric rheumatic disease. However, long-term safety data in children remain limited for several agents. With any therapeutic option, both short-term and long-term safety concerns must be weighed against individual clinical needs when choosing the optimal treatment for each child.

show abstract

Section: Costimulatory Inhibitorsmentioning

confidence: 99%

Section: Costimulatory Inhibitorsmentioning

confidence: 99%

Section: Costimulatory Inhibitorsmentioning

confidence: 99%

Section: Costimulatory Inhibitorsmentioning

confidence: 99%

Section: Costimulatory Inhibitorsmentioning

confidence: 99%

See 3 more Smart Citations

Safety updates in novel therapeutics for pediatric rheumatic disease

Randell

Becker

2021

Current Opinion in Rheumatology

View full text Add to dashboard Cite

show abstract

Monoclonal Antibodies to CTLA-4 with Focus on Ipilimumab

Graziani

Lisi

Tentori

et al. 2022

Experientia Supplementum

View full text Add to dashboard Cite

Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4 or CD152) is a negative regulator of T-cell mediated immune responses, which plays a critical role in suppressing autoimmunity and maintaining immune homeostasis. Because of its inhibitory activity on T cells, CTLA-4 has been investigated as a drug target to induce immunostimulation, blocking the interaction with its ligands. The antitumour effects mediated by CTLA-4 blockade have been attributed to a sustained active immune response against cancer cells, due to the release of a brake on T cell activation. Ipilimumab (Yervoy, Bristol-Myers Squibb) is a fully human monoclonal IgG1κ antibody against CTLA-4 approved by FDA and EMA in 2011 for the treatment of advanced (unresectable or metastatic) melanoma, based on the increase of overall survival demonstrated in a phase III clinical trial. Further development of ipilimumab includes its use in other refractory and advanced solid tumours, either as monotherapy or in combination with additional immunostimulating agents or molecularly targeted therapies.

show abstract